Fundz

Nanopath announces the close of a $25 million Series B financing to advance molecular testing for women's health, co-led by Norwest and SV Health Investors.

PRIVATENov 10, 2026

Amount Raised

$25 Million

Round Type

Series B

CambridgeBiotechnologyHealth Care

Investors

Alumni VenturesGingerbread CapitalElderberry VenturesLabcorp Venture FundSV Health Investors' Medtech Convergence FundNorwest Venture Partners

Description

Nanopath, a point-of-care diagnostics company, has closed a $25 million Series B financing round to support the launch of its FDA 510(k) study for a new vaginitis test. The round was co-led by Norwest and SV Health Investors' MedTech Convergence Fund, with participation from other investors. This funding will also aid in the potential expansion of Nanopath's pipeline and the growth of its team in preparation for commercialization.

Quick answer

Nanopath raised $25 Million in a Series B round, dated November 10, 2026. Investors: Alumni Ventures, Gingerbread Capital, Elderberry Ventures, Labcorp Venture Fund, SV Health Investors' Medtech Convergence Fund and Norwest Venture Partners. Nanopath is based in Cambridge, Massachusetts, United States.

How much did Nanopath raise?
Nanopath raised $25 Million in a Series B round on November 10, 2026.
Who invested in Nanopath?
Alumni Ventures, Gingerbread Capital, Elderberry Ventures, Labcorp Venture Fund, SV Health Investors' Medtech Convergence Fund and Norwest Venture Partners are named as investors in this round.
What does Nanopath do?
Nanopath is a molecular diagnostics company disrupting traditional testing methodologies.
Where is Nanopath based and how big is it?
Nanopath is based in Cambridge, Massachusetts, United States. Fundz records about 25 employees.
Who are the decision-makers at Nanopath?
Fundz holds 2 contacts at Nanopath, including the Co-Founder & CEO. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Nanopath that raised within 45 days of this round, from Fundz verified event records.

  • Efferon raised $4.8M (Seed) on November 10, 2026.
  • EnVision Endoscopy raised $12M (Series A) on November 10, 2026.
  • Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
  • Neobe raised $6.8M on November 10, 2026.
  • MyoWorks raised an undisclosed amount on November 10, 2026.
  • Mosaic Intelligence Labs raised $47M (Seed) on November 10, 2026.

Who to call at Nanopath, and when

A new round usually means Nanopath is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Nanopath raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nanopath, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nanopath. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nanopath

Location

Cambridge, Massachusetts, United States

About

Nanopath is a molecular diagnostics company disrupting traditional testing methodologies. We aim to improve the health of women by providing granular and clinically actionable information within a single office visit.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nanopath raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsAmogha T., Co-Founder & CEOSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Nanopath's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Nanopath raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.